{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:02Z","timestamp":1792601582619,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98717","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:03:23Z","timestamp":1765206203000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management"],"prefix":"10.7759","author":[{"given":"Pooja","family":"SirDeshpande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soorya Bavikeri Shivakumara","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0489","article-title":"Endocrine toxicity of cancer immunotherapy: Clinical challenges","volume":"10","author":"Anderson B","year":"2021","unstructured":"Anderson B, Morganstein DL. Endocrine toxicity of cancer immunotherapy: Clinical challenges. Endocr Connect. 2021, 10:R116-24. 10.1530\/EC-20-0489","journal-title":"Endocr Connect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti F","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, et al.. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019, 26:G1-G18. 10.1530\/ERC-18-0320","journal-title":"Endocr Relat Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield JA","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K, et al.. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005, 28:593-8. 10.1097\/01.cji.0000178913.41256.06","journal-title":"J Immunother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang JC","year":"2007","unstructured":"Yang JC, Hughes M, Kammula U, et al.. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007, 30:825-30. 10.1097\/CJI.0b013e318156e47e","journal-title":"J Immunother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard T","year":"2010","unstructured":"Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010, 13:29-38. 10.1007\/s11102-009-0193-z","journal-title":"Pituitary"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy","volume":"121","author":"Lammert A","year":"2013","unstructured":"Lammert A, Schneider HJ, Bergmann T, et al.. Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes. 2013, 121:581-7. 10.1055\/s-0033-1355337","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz Y","year":"2014","unstructured":"Chodakiewitz Y, Brown S, Boxerman JL, Brody JM, Rogg JM. Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis. Clin Neurol Neurosurg. 2014, 125:125-30. 10.1016\/j.clineuro.2014.06.011","journal-title":"Clin Neurol Neurosurg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama S","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014, 6:230ra45. 10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje AT","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014, 99:4078-85. 10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: Review of the literature","volume":"38","author":"Araujo PB","year":"2015","unstructured":"Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: Review of the literature. J Endocrinol Invest. 2015, 38:1159-66. 10.1007\/s40618-015-0301-z","journal-title":"J Endocrinol Invest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12819","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series","volume":"45","author":"Lam T","year":"2015","unstructured":"Lam T, Chan MM, Sweeting AN, et al.. Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. Intern Med J. 2015, 45:1066-73. 10.1111\/imj.12819","journal-title":"Intern Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel F","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, et al.. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015, 172:195-204. 10.1530\/EJE-14-0845","journal-title":"Eur J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study","volume":"21","author":"Min L","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, et al.. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin Cancer Res. 2015, 21:749-55. 10.1158\/1078-0432.CCR-14-2353","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje A","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights. Pituitary. 2016, 19:82-92. 10.1007\/s11102-015-0671-4","journal-title":"Pituitary"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari M","year":"2015","unstructured":"Mahzari M, Liu D, Arnaout A, Lochnan H. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015, 8:21-8. 10.4137\/CMED.S22469","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli L","year":"2017","unstructured":"Brilli L, Danielli R, Ciuoli C, et al.. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017, 58:535-41. 10.1007\/s12020-017-1289-2","journal-title":"Endocrine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"De Sousa SM","year":"2018","unstructured":"De Sousa SM, Sheriff N, Tran CH, Menzies AM, Tsang VH, Long GV, Tonks KT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018, 21:274-82. 10.1007\/s11102-018-0866-6","journal-title":"Pituitary"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje AT","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, et al.. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018, 124:3706-14. 10.1002\/cncr.31629","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00978-4","article-title":"Ipilimumab-induced hypophysitis, a single academic center experience","volume":"22","author":"Snyders T","year":"2019","unstructured":"Snyders T, Chakos D, Swami U, et al.. Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary. 2019, 22:488-96. 10.1007\/s11102-019-00978-4","journal-title":"Pituitary"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2020.1817064","article-title":"Primary and ipilimumab-induced hypophysitis: A single-center case series","volume":"45","author":"Atkins P","year":"2020","unstructured":"Atkins P, Ur E. Primary and ipilimumab-induced hypophysitis: A single-center case series. Endocr Res. 2020, 45:246-53. 10.1080\/07435800.2020.1817064","journal-title":"Endocr Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje A","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al.. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019, 181:211-9. 10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: Insights from four cases","volume":"2019","author":"Lupi I","year":"2019","unstructured":"Lupi I, Brancatella A, Cosottini M, et al.. Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: Insights from four cases. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0102","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103280","article-title":"Anti-PD1 and anti-PDL1-induced hypophysitis: A cohort study of 17 patients with longitudinal follow-up","volume":"9","author":"Levy M","year":"2020","unstructured":"Levy M, Abeillon J, Dalle S, et al.. Anti-PD1 and anti-PDL1-induced hypophysitis: A cohort study of 17 patients with longitudinal follow-up. J Clin Med. 2020, 9:3280. 10.3390\/jcm9103280","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164036","article-title":"Hypothalamic-pituitary autoimmunity in patients treated with anti-PD-1 and anti-PD-L1 antibodies","volume":"13","author":"Bellastella G","year":"2021","unstructured":"Bellastella G, Carbone C, Scappaticcio L, et al.. Hypothalamic-pituitary autoimmunity in patients treated with anti-PD-1 and anti-PD-L1 antibodies. Cancers. 2021, 13:4036. 10.3390\/cancers13164036","journal-title":"Cancers"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_831_21","article-title":"Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy","volume":"18","author":"Han X","year":"2022","unstructured":"Han X, Meng M, Zhang T, et al.. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy. J Cancer Res Ther. 2022, 18:1440-3. 10.4103\/jcrt.jcrt_831_21","journal-title":"J Cancer Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01397-0","article-title":"Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies","volume":"23","author":"Chen H","year":"2023","unstructured":"Chen H, Zhang L, Zhao L, Li X. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies. BMC Endocr Disord. 2023, 23:139. 10.1186\/s12902-023-01397-0","journal-title":"BMC Endocr Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15075","article-title":"Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis","volume":"101","author":"Yang L","year":"2024","unstructured":"Yang L, Zhang Y, Chen X, Liu K, Zhou Y, Wang S. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis. Clin Endocrinol (Oxf). 2024, 101:130-9. 10.1111\/cen.15075","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1490042","article-title":"Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: A prospective study with immortal time bias correction","volume":"15","author":"Suzuki K","year":"2024","unstructured":"Suzuki K, Kobayashi T, Izuchi T, et al.. Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: A prospective study with immortal time bias correction. Front Endocrinol (Lausanne). 2024, 15:1490042. 10.3389\/fendo.2024.1490042","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71699","article-title":"Comparison of magnetic resonance imaging features between programmed cell death 1\/programmed cell death ligand 1 inhibitor-induced hypopituitarism and idiopathic hypopituitarism in Japanese subjects","volume":"16","author":"Iwamoto Y","year":"2024","unstructured":"Iwamoto Y, Kimura T, Dan K, et al.. Comparison of magnetic resonance imaging features between programmed cell death 1\/programmed cell death ligand 1 inhibitor-induced hypopituitarism and idiopathic hypopituitarism in Japanese subjects. Cureus. 2024, 16:e71699. 10.7759\/cureus.71699","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.03.048","article-title":"Pituitary dysfunction: A case series of immune checkpoint inhibitor-related hypophysitis in an emergency department","volume":"68","author":"Miller AH","year":"2016","unstructured":"Miller AH, Brock P, Jim Yeung SC. Pituitary dysfunction: A case series of immune checkpoint inhibitor-related hypophysitis in an emergency department. Ann Emerg Med. 2016, 68:249-50. 10.1016\/j.annemergmed.2016.03.048","journal-title":"Ann Emerg Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli P","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al.. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am J Pathol. 2016, 186:3225-35. 10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11814","article-title":"Adrenal insufficiency related to anti-programmed death-1 therapy","volume":"37","author":"Ariyasu R","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, et al.. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 2017, 37:4229-32. 10.21873\/anticanres.11814","journal-title":"Anticancer Res"},{"key":"ref37","article-title":"Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors\u00b4 treatment: Spectrum of imaging appearances","volume":"39","author":"Malikova H","year":"2018","unstructured":"Malikova H, Holesta M, Fialova A, Arenbergerova M, Weichet J. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors\u00b4 treatment: Spectrum of imaging appearances. Neur Endocrinol Lett. 2018, 39:196-204.","journal-title":"Neur Endocrinol Lett"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment","volume":"14","author":"Di Dalmazi G","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment. Expert Rev Endocrinol Metab. 2019, 14:381-98. 10.1080\/17446651.2019.1701434","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.03.002","article-title":"Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis","volume":"113","author":"Guerrero E","year":"2019","unstructured":"Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. Eur J Cancer. 2019, 113:10-3. 10.1016\/j.ejca.2019.03.002","journal-title":"Eur J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: A retrospective analysis of the French Pharmacovigilance database","volume":"9","author":"Garon-Czmil J","year":"2019","unstructured":"Garon-Czmil J, Petitpain N, Rouby F, et al.. Immune check point inhibitors-induced hypophysitis: A retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019, 9:19419. 10.1038\/s41598-019-56026-5","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.020","article-title":"Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy","volume":"119","author":"Mekki A","year":"2019","unstructured":"Mekki A, Dercle L, Lichtenstein P, et al.. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer. 2019, 119:44-56. 10.1016\/j.ejca.2019.06.020","journal-title":"Eur J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2018-0009","article-title":"Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population","volume":"6","author":"Wei KZ","year":"2019","unstructured":"Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Manag. 2019, 6:MMT13. 10.2217\/mmt-2018-0009","journal-title":"Melanoma Manag"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8","volume":"6","author":"Leiter A","year":"2020","unstructured":"Leiter A, Gnjatic S, Fowkes M, Kim-Schulze S, Laface I, Galsky MD, Gallagher EJ. A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8. AACE Clin Case Rep. 2020, 6:e151-60. 10.4158\/ACCR-2019-0585","journal-title":"AACE Clin Case Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01297-3","article-title":"Predicting development of ipilimumab-induced hypophysitis: Utility of T4 and TSH index but not TSH","volume":"44","author":"Siddiqui MS","year":"2021","unstructured":"Siddiqui MS, Lai ZM, Spain L, Greener V, Turajlic S, Larkin J, Morganstein DL. Predicting development of ipilimumab-induced hypophysitis: Utility of T4 and TSH index but not TSH. J Endocrinol Invest. 2021, 44:195-203. 10.1007\/s40618-020-01297-3","journal-title":"J Endocrinol Invest"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: An observational, retrospective, disproportionality study","volume":"43","author":"Bai X","year":"2020","unstructured":"Bai X, Chen X, Wu X, et al.. Immune checkpoint inhibitor-associated pituitary adverse events: An observational, retrospective, disproportionality study. J Endocrinol Invest. 2020, 43:1473-83. 10.1007\/s40618-020-01226-4","journal-title":"J Endocrinol Invest"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study","volume":"8","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al.. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study. J Immunother Cancer. 2020, 8:e000779. 10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano S","year":"2020","unstructured":"Yano S, Ashida K, Sakamoto R, et al.. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020, 130:198-203. 10.1016\/j.ejca.2020.02.049","journal-title":"Eur J Cancer"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6692","article-title":"MRI findings of immune checkpoint inhibitor-induced hypophysitis: Possible association with fibrosis","volume":"41","author":"Kurokawa R","year":"2020","unstructured":"Kurokawa R, Ota Y, Gonoi W, et al.. MRI findings of immune checkpoint inhibitor-induced hypophysitis: Possible association with fibrosis. AJNR Am J Neuroradiol. 2020, 41:1683-9. 10.3174\/ajnr.A6692","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0760","article-title":"Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis","volume":"186","author":"Seejore K","year":"2021","unstructured":"Seejore K, Giannoudi M, Osborn D, et al.. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis. Eur J Endocrinol. 2021, 186:83-93. 10.1530\/EJE-21-0760","journal-title":"Eur J Endocrinol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: Lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal A","year":"2022","unstructured":"Kotwal A, Rouleau SG, Dasari S, et al.. Immune checkpoint inhibitor-induced hypophysitis: Lessons learnt from a large cancer cohort. J Investig Med. 2022, 70:939-46. 10.1136\/jim-2021-002099","journal-title":"J Investig Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome","volume":"70","author":"Kanie K","year":"2021","unstructured":"Kanie K, Iguchi G, Bando H, et al.. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome. Cancer Immunol Immunother. 2021, 70:3669-77. 10.1007\/s00262-021-02955-y","journal-title":"Cancer Immunol Immunother"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis\u2014a multicenter retrospective study","volume":"25","author":"Amereller F","year":"2022","unstructured":"Amereller F, Deutschbein T, Joshi M, et al.. Differences between immunotherapy-induced and primary hypophysitis\u2014a multicenter retrospective study. Pituitary. 2022, 25:152-8. 10.1007\/s11102-021-01182-z","journal-title":"Pituitary"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review","volume":"24","author":"Iglesias P","year":"2021","unstructured":"Iglesias P, S\u00e1nchez JC, D\u00edez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: A systematic review. Pituitary. 2021, 24:630-43. 10.1007\/s11102-021-01141-8","journal-title":"Pituitary"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0228","article-title":"Immunotherapy-induced isolated ACTH deficiency in cancer therapy","volume":"28","author":"Iglesias P","year":"2021","unstructured":"Iglesias P, Peir\u00f3 I, Biagetti B, et al.. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Endocr Relat Cancer. 2021, 28:783-92. 10.1530\/ERC-21-0228","journal-title":"Endocr Relat Cancer"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab141","article-title":"Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy","volume":"51","author":"Takagi T","year":"2021","unstructured":"Takagi T, Yoshida K, Kondo T, et al.. Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. Jpn J Clin Oncol. 2021, 51:1744-50. 10.1093\/jjco\/hyab141","journal-title":"Jpn J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: Diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen H","year":"2021","unstructured":"Nguyen H, Shah K, Waguespack SG, et al.. Immune checkpoint inhibitor related hypophysitis: Diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021, 28:419-31. 10.1530\/ERC-20-0513","journal-title":"Endocr Relat Cancer"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi T","year":"2021","unstructured":"Kobayashi T, Iwama S, Sugiyama D, et al.. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002493. 10.1136\/jitc-2021-002493","journal-title":"J Immunother Cancer"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05400-x","article-title":"Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: A retrospective cohort study","volume":"12","author":"Takayasu S","year":"2022","unstructured":"Takayasu S, Mizushiri S, Watanuki Y, et al.. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: A retrospective cohort study. Sci Rep. 2022, 12:1294. 10.1038\/s41598-022-05400-x","journal-title":"Sci Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070370","article-title":"Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: An endocrinology perspective for oncologists","volume":"29","author":"Druce I","year":"2022","unstructured":"Druce I, Tawagi K, Shaw JL, Ibrahim A, Lochnan H, Ong M. Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: An endocrinology perspective for oncologists. Curr Oncol. 2022, 29:4665-77. 10.3390\/curroncol29070370","journal-title":"Curr Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel S","year":"2022","unstructured":"Jessel S, Weiss SA, Austin M, et al.. Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function. Front Oncol. 2022, 12:836859. 10.3389\/fonc.2022.836859","journal-title":"Front Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01845-z","article-title":"Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: A retrospective analysis using the FAERS","volume":"45","author":"Lu D","year":"2022","unstructured":"Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: A retrospective analysis using the FAERS. J Endocrinol Invest. 2022, 45:2131-7. 10.1007\/s40618-022-01845-z","journal-title":"J Endocrinol Invest"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041057","article-title":"Immune checkpoint inhibitors as a threat to the hypothalamus-pituitary axis: A completed puzzle","volume":"14","author":"Barnabei A","year":"2022","unstructured":"Barnabei A, Corsello A, Paragliola RM, Iannantuono GM, Falzone L, Corsello SM, Torino F. Immune checkpoint inhibitors as a threat to the hypothalamus-pituitary axis: A completed puzzle. Cancers. 2022, 14:1057. 10.3390\/cancers14041057","journal-title":"Cancers"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.798517","article-title":"Immune checkpoint inhibitor-induced central diabetes insipidus: Looking for the needle in the haystack or a very rare side-effect to promptly diagnose?","volume":"12","author":"Barnabei A","year":"2022","unstructured":"Barnabei A, Strigari L, Corsello A, et al.. Immune checkpoint inhibitor-induced central diabetes insipidus: Looking for the needle in the haystack or a very rare side-effect to promptly diagnose?. Front Oncol. 2022, 12:798517. 10.3389\/fonc.2022.798517","journal-title":"Front Oncol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01024-4","article-title":"Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma","volume":"22","author":"Yamada H","year":"2022","unstructured":"Yamada H, Washino S, Suzuki D, et al.. Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma. BMC Endocr Disord. 2022, 22:110. 10.1186\/s12902-022-01024-4","journal-title":"BMC Endocr Disord"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01231-1","article-title":"HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency","volume":"25","author":"Ono M","year":"2022","unstructured":"Ono M, Fukuda I, Nagao M, et al.. HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency. Pituitary. 2022, 25:615-21. 10.1007\/s11102-022-01231-1","journal-title":"Pituitary"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad012","article-title":"Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis","volume":"7","author":"Quandt Z","year":"2023","unstructured":"Quandt Z, Kim S, Villanueva-Meyer J, et al.. Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis. J Endocr Soc. 2023, 7:bvad012. 10.1210\/jendso\/bvad012","journal-title":"J Endocr Soc"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2022-0429","article-title":"Immune checkpoint inhibitor-mediated hypophysitis: No place like home","volume":"23","author":"Cooksley T","year":"2023","unstructured":"Cooksley T, Knight T, Lindsay D, et al.. Immune checkpoint inhibitor-mediated hypophysitis: No place like home. Clin Med (Lond). 2023, 23:81-4. 10.7861\/clinmed.2022-0429","journal-title":"Clin Med (Lond)"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: Diagnostic challenges and link with survival","volume":"21","author":"Johnson J","year":"2023","unstructured":"Johnson J, Goldner W, Abdallah D, Qiu F, Ganti AK, Kotwal A. Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: Diagnostic challenges and link with survival. J Natl Compr Canc Netw. 2023, 21:281-7. 10.6004\/jnccn.2022.7098","journal-title":"J Natl Compr Canc Netw"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030415","article-title":"Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: Two sides of the same coin?","volume":"13","author":"Chiloiro S","year":"2023","unstructured":"Chiloiro S, Giampietro A, Bianchi A, et al.. Pituitary enlargement and hypopituitarism in patients treated with immune checkpoint inhibitors: Two sides of the same coin?. J Pers Med. 2023, 13:415. 10.3390\/jpm13030415","journal-title":"J Pers Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120766","article-title":"Exploring a rarity: Incidence of and therapeutic approaches for neurological complications and hypophysitis in cancer patients on immune checkpoint inhibitors\u2014A single-center study","volume":"30","author":"Amylidi AL","year":"2023","unstructured":"Amylidi AL, Gogadis A, Yerolatsite M, et al.. Exploring a rarity: Incidence of and therapeutic approaches for neurological complications and hypophysitis in cancer patients on immune checkpoint inhibitors\u2014A single-center study. Curr Oncol. 2023, 30:10509-18. 10.3390\/curroncol30120766","journal-title":"Curr Oncol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103387","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: A positive predictor of survival among cancer patients treated with checkpoint inhibitors","volume":"22","author":"Aviv-Shimoni S","year":"2023","unstructured":"Aviv-Shimoni S, Uri I, Milloh-Raz H, Percik R. Isolated autoimmune adrenocorticotropic hormone deficiency: A positive predictor of survival among cancer patients treated with checkpoint inhibitors. Autoimmun Rev. 2023, 22:103387. 10.1016\/j.autrev.2023.103387","journal-title":"Autoimmun Rev"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1295865","article-title":"Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis","volume":"14","author":"Galligan A","year":"2023","unstructured":"Galligan A, Iravani A, Lasocki A, et al.. Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. Front Endocrinol. 2023, 14:1295865. 10.3389\/fendo.2023.1295865","journal-title":"Front Endocrinol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03394-8","article-title":"Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: A single center prospective study","volume":"81","author":"Hara N","year":"2023","unstructured":"Hara N, Suwanai H, Yakou F, et al.. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: A single center prospective study. Endocrine. 2023, 81:477-83. 10.1007\/s12020-023-03394-8","journal-title":"Endocrine"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005440","article-title":"18 F-FDG PET\/CT for detection of immunotherapy-induced hypophysitis\u2014A case-control study","volume":"49","author":"Fischer A","year":"2024","unstructured":"Fischer A, Mart\u00ednez-G\u00f3mez JM, Mangana J, et al.. 18 F-FDG PET\/CT for detection of immunotherapy-induced hypophysitis\u2014A case-control study. Clin Nucl Med. 2024, 49:e656-63. 10.1097\/RLU.0000000000005440","journal-title":"Clin Nucl Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2180","article-title":"Combined PD-1 and CTLA-4 blockade increases the risks of multiple pituitary hormone deficiency and isolated adrenocorticotropic deficiency: A prospective study","volume":"40","author":"Iwama S","year":"2025","unstructured":"Iwama S, Kobayashi T, Izuchi T, et al.. Combined PD-1 and CTLA-4 blockade increases the risks of multiple pituitary hormone deficiency and isolated adrenocorticotropic deficiency: A prospective study. Endocrinol Metab. 2025, 40:459-68. 10.3803\/EnM.2024.2180","journal-title":"Endocrinol Metab"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0223","article-title":"Immune checkpoint inhibitor induced hypophysitis: A specific disease of corticotrophs?","volume":"13","author":"Patel N","year":"2024","unstructured":"Patel N, Hirwa K, Gardner G, Pearce K, Jeffery J, Iqbal F, Flanagan D. Immune checkpoint inhibitor induced hypophysitis: A specific disease of corticotrophs?. Endocr Connect. 2024, 13:10.1530\/EC-24-0223","journal-title":"Endocr Connect"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071340","article-title":"Early serum markers for immune checkpoint inhibitor induced hypophysitis in melanoma patients","volume":"16","author":"Mitri F","year":"2024","unstructured":"Mitri F, Machiraju D, Naoum C, Hassel JC. Early serum markers for immune checkpoint inhibitor induced hypophysitis in melanoma patients. Cancers. 2024, 16:1340. 10.3390\/cancers16071340","journal-title":"Cancers"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1400841","article-title":"Differences in checkpoint-inhibitor-induced hypophysitis: Mono- versus combination therapy induced hypophysitis","volume":"15","author":"van der Leij S","year":"2024","unstructured":"van der Leij S, Suijkerbuijk KP, van den Broek MF, Valk GD, Dankbaar JW, van Santen HM. Differences in checkpoint-inhibitor-induced hypophysitis: Mono- versus combination therapy induced hypophysitis. Front Endocrinol (Lausanne). 2024, 15:1400841. 10.3389\/fendo.2024.1400841","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.523","article-title":"Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor","volume":"39","author":"Sang H","year":"2024","unstructured":"Sang H, Cho YK, Go SH, Kim HJ, Koh EH. Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor. Korean J Intern Med. 2024, 39:801-12. 10.3904\/kjim.2023.523","journal-title":"Korean J Intern Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1326684","article-title":"Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: A systematic review","volume":"15","author":"Wang F","year":"2024","unstructured":"Wang F, Shi X, Yu X, Yang Y. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: A systematic review. Front Endocrinol (Lausanne). 2024, 15:1326684. 10.3389\/fendo.2024.1326684","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008634","article-title":"Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis","volume":"12","author":"Bando H","year":"2024","unstructured":"Bando H, Yamamoto M, Urai S, et al.. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis. J Immunother Cancer. 2024, 12:e008634. 10.1136\/jitc-2023-008634","journal-title":"J Immunother Cancer"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2453829","article-title":"High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial","volume":"57","author":"Theiler-Schwetz V","year":"2025","unstructured":"Theiler-Schwetz V, Trummer C, Schmitt L, Terbuch A, Obermayer-Pietsch B, Richtig E, Pilz S. High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial. Ann Med. 2025, 57:2453829. 10.1080\/07853890.2025.2453829","journal-title":"Ann Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037587","article-title":"The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database","volume":"103","author":"Tang Q","year":"2024","unstructured":"Tang Q, Han Y, Song M, Peng J, Zhang M, Ren X, Sun H. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database. Medicine (Baltimore). 2024, 103:e37587. 10.1097\/MD.0000000000037587","journal-title":"Medicine (Baltimore)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15240","article-title":"The utility of magnetic resonance imaging for hypophysitis secondary to immune checkpoint inhibitor use","volume":"102","author":"Qi QY","year":"2025","unstructured":"Qi QY, Vettivel J, Solanki K, Davis A, Russell AW, Bach LA. The utility of magnetic resonance imaging for hypophysitis secondary to immune checkpoint inhibitor use. Clin Endocrinol (Oxf). 2025, 102:699-705. 10.1111\/cen.15240","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis","volume":"2","author":"Kanie K","year":"2018","unstructured":"Kanie K, Iguchi G, Bando H, et al.. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2018, 2:91-5. 10.1210\/js.2017-00414","journal-title":"J Endocr Soc"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-022-06911-x","article-title":"Anti-PD-L1 therapy-associated hypophysitis and limbic encephalitis","volume":"48","author":"Matthys A","year":"2022","unstructured":"Matthys A, Demeret S, Leclercq D, Di Meglio L. Anti-PD-L1 therapy-associated hypophysitis and limbic encephalitis. Intensive Care Med. 2022, 48:1807-8. 10.1007\/s00134-022-06911-x","journal-title":"Intensive Care Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001529","article-title":"Durvalumab-associated hypopituitarism","volume":"30","author":"Ogbue O","year":"2023","unstructured":"Ogbue O, Garisa M, Furqan M, Alqaisi S, Patel R. Durvalumab-associated hypopituitarism. Am J Ther. 2023, 30:e583-6. 10.1097\/MJT.0000000000001529","journal-title":"Am J Ther"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01775-0","article-title":"Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma","volume":"16","author":"Furuichi N","year":"2023","unstructured":"Furuichi N, Naganuma A, Kaburagi T, et al.. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Clin J Gastroenterol. 2023, 16:422-31. 10.1007\/s12328-023-01775-0","journal-title":"Clin J Gastroenterol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad157","article-title":"Iatrogenic pituitary shutdown: A rare adverse event of programmed cell death-ligand 1 inhibitor","volume":"2","author":"Al-Hiari M","year":"2024","unstructured":"Al-Hiari M, Workman A, Ezeh E, Teka S. Iatrogenic pituitary shutdown: A rare adverse event of programmed cell death-ligand 1 inhibitor. JCEM Case Rep. 2024, 2:luad157. 10.1210\/jcemcr\/luad157","journal-title":"JCEM Case Rep"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0513","article-title":"Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Percik R","year":"2023","unstructured":"Percik R, Criseno S, Adam S, Young K, Morganstein DL. Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. Endocr Connect. 2023, 12:10.1530\/EC-22-0513","journal-title":"Endocr Connect"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation","volume":"33","author":"Gubbi S","year":"2019","unstructured":"Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab. 2019, 33:101371. 10.1016\/j.beem.2019.101371","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.03.023","article-title":"Endocrinopathies associated with immune checkpoint inhibitor use","volume":"30","author":"Kotwal A","year":"2024","unstructured":"Kotwal A, Kennedy R, Kikani N, Thosani S, Goldner W, Shariff A. Endocrinopathies associated with immune checkpoint inhibitor use. Endocr Pract. 2024, 30:584-91. 10.1016\/j.eprac.2024.03.023","journal-title":"Endocr Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/436907-immune-checkpoint-inhibitor-related-hypophysitis-and-pituitary-dysfunction-a-systematic-review-of-diagnosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:03:24Z","timestamp":1765206204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/436907-immune-checkpoint-inhibitor-related-hypophysitis-and-pituitary-dysfunction-a-systematic-review-of-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":92,"URL":"https:\/\/doi.org\/10.7759\/cureus.98717","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}